Vaxil Bio Ltd. (VXL.V)
Vaxil Bio Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $0.17, up 0.00% on the session, giving a market capitalisation of $697,204. Its beta of -0.88 implies it has historically moved less than the broad market.
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
Vaxil Bio Ltd. is most often compared with the following Healthcare names: